抗犬细小病毒单克隆抗体的制备与鉴定

为制备针对犬细小病毒(CPV)的单克隆抗体,以纯化的CPV免疫BALB/c小鼠,3次免疫后,取其脾细胞与SP2/0细胞进行细胞融合。利用超速离心纯化的病毒作为包被抗原,采用间接ELISA方法筛选阳性杂交瘤细胞,获得3株能稳定分泌单克隆抗体的杂交瘤细胞株,分别命名为1D9、3G9和4F6。单克隆抗体细胞培养上清效价为1∶64、1∶64、1∶128,腹水效价为1∶10~4、1∶10~4、1∶10~5。3株杂交瘤细胞的染色体数分别为92、94、98。亚类鉴定结果显示1D9和3G9重链为IgG1,4F6重链为IgG2b,轻链均为kappa链。病毒中和试验表明,单克隆抗体4F6对CPV具有明显的病毒中和活性。交叉试验表明,3株单克隆抗体均可与CPV特异性结合,与其他犬类常见病毒无交叉反应。本研究制备的单克隆抗体为CPV的检测及其感染动物的治疗提供了物质基础。     

犬细小病毒单克隆抗体的制备及其在胶体金免疫层析试纸研发中的应用

为制备犬细小病毒胶体金免疫层析试纸,将F81细胞中分离的CPV免疫Balb/c小鼠,取其脾细胞与骨髓瘤细胞融合,建立间接ELISA方法筛选分泌CPV单克隆抗体的杂交瘤细胞,获得1株能稳定分泌CPV单克隆抗体的杂交瘤细胞株,命名为3E2。3E2的亚类为IgG1型,腹水抗体效价为1.8×105,交叉试验表明,3E2可与CPV特异性结合,与其他犬常见病毒无交叉反应。用3E2单克隆抗体制备的检测CPV的胶体金免疫层析试纸条特异性良好,为诊断和研究CPV奠定了基础。     

伪狂犬病病毒闽A株单克隆抗体的制备与鉴定

本试验应用细胞杂交瘤技术,取健康BALB/c小鼠脾细胞与SP2/0骨髓瘤细胞进行细胞融合,经双抗体夹心ELISA筛选,4次有限稀释法克隆,得到2株能稳定分泌抗伪狂犬病病毒(PRV)的单克隆抗体杂交瘤细胞株:2C6E6、3D5F1。2株杂交瘤细胞培养上清的效价分别为1∶512、1∶1 024。鉴定结果显示这2株单克隆抗体分别为IgG1亚类和IgG2a亚类,杂交瘤细胞的平均染色体数目为84条。用纯化的PRV免疫经产健康的BALB/c小鼠,采用ELISA方法检测获得的腹水的效价分别为1∶1 638 400和1∶819 200。经检测这2株单克隆抗体与猪瘟病毒、猪繁殖与呼吸综合征病毒、猪细小病毒均不发生交叉反应,特异性良好。杂交瘤细胞连续培养30代,仍能稳定分泌抗PRV的单克隆抗体,说明这2株单克隆抗体的稳定性良好。本试验研究结果为PRV的快速诊断方法的建立奠定了理论基础。     

猪繁殖与呼吸综合征病毒N蛋白单克隆抗体的制备及生物学特性分析

分别用纯化的猪繁殖与呼吸综合征病毒(PRRSV)和纯化的重组N蛋白免疫BALB/c小鼠,采用杂交瘤技术制备抗PRRSV N蛋白的单克隆抗体(McAb)。用纯化的PRRSV免疫小鼠,经细胞融合获得2株可分泌特异性单抗的杂交瘤细胞株,分别命名为4B8、4D8。用重组N蛋白免疫的小鼠,经细胞融合获得3株可分泌特异性McAb的抗PRRSV N蛋白的杂交瘤细胞2F3、4D5、5D11。间接ELISA检测4D8、4B8、4D5和5D11杂交瘤上清效价为1∶32~1∶512,而2F3的腹水效价为1∶12 800。单抗2F3、4B8和4D8与纯化病毒的Western blotting反应都为阳性,而4D5和5D11为阴性。IFA检测结果5株单抗都有明显的荧光,与PRRSV呈阳性反应。2F3的Ig亚型为IgM。5株单抗杂交瘤细胞连续传代至20代,分泌相应McAb的效价基本一致。本研究为PRRSV生物学诊断和方法研究提供有用工具。     

犬瘟热病毒单克隆抗体的制备和鉴定

将从水貂中分离的犬瘟热病毒(CDV) HB株,以培养纯化的犬瘟热病毒HB株免疫BALB/c小鼠,采用B淋巴细胞杂交瘤技术,通过ELISA筛选,获得3株能稳定分泌抗犬瘟热病毒结构蛋白的单克隆抗体杂交瘤细胞株.3株单克隆抗体菌属于IgG1亚类,其腹水效价可达到1∶51 200和1:204 800,细胞培养上清液效价可达到1:256和1:512.ELISA分析表明,单抗仅与CDV发生特异性反应,而与犬细小病毒(CPV)和犬腺毒(CAV)没有交叉反应;荧光免疫染色检测进一步表明单克隆抗体的特异性好.该特异性单抗的制备为建立有效检测犬瘟热病毒感染的方法奠定基础.     

抗水牛伊氏锥虫变异表面糖蛋白抗原单克隆抗体的研制

用纯化的伊氏锥虫变异表面糖蛋白（variant surface glucoprotein, VSG）免疫BALB/c小鼠,取免疫小鼠脾细胞与SP2/0骨髓瘤细胞进行融合,经过3次克隆和间接ELISA方法筛选,获得3D7、5B9 2株稳定分泌单克隆抗体的杂交瘤细胞株,用间接ELISA方法检测杂交瘤细胞培养液上清效价和小鼠腹水效价,其中细胞培养上清效价分别为1∶6400和1∶12800,腹水效价分别为1∶105和1∶106。单抗的亚型鉴定结果表明,3D7、5B9分泌的抗体都为IgG1亚类κ链。     

分泌抗犬细小病毒单克隆抗体杂交瘤细胞株的建立

将用犬细小病毒(CPV)免疫的BALB/C小鼠脾细胞与SP2/0细胞在聚乙二醇作用下融合,用血凝抑制试验(HI)筛选,以有限稀释法克隆3次,得到6株分泌抗CPV单克隆抗体(McAb)的杂交瘤细胞,其中4株分泌IgG_1,2株分泌IgM;6株杂交瘤细胞染色体数目介于96—103之间;在半年传代期间(45代),均能稳定地分泌McAb。将杂交瘤细胞注射BALB/C小鼠诱生腹水,其HI效价介于1:128—1:512之间,置-20℃保存1年,其效价不变。用交又HI法对2株单克隆抗体作特异性分析,该McAb只特异地与CPV发生反应,而不与猫泛白细胞减少症病毒(FPLV)、水貂肠炎病毒(MEV)发生反应。     

猪流行性腹泻病毒S蛋白中和表位区单克隆抗体的制备与鉴定

以纯化的猪流行性腹泻病毒(Porcine epidemic diarrhea virus,PEDV)S蛋白中和表位(SID)重组蛋白为抗原免疫BALB/c小鼠,利用淋巴细胞杂交瘤技术获得了6株稳定分泌抗SID区特异性的单克隆抗体细胞株,分别命名为2C4、3G3、5F8、3G5、6E6和3C3。6株杂交瘤细胞诱生小鼠产生的腹水抗体效价分别为1∶51200、1∶6400、1∶12800、1∶6400、1∶51200和1∶25600。免疫球蛋白类型均为IgG1型,轻链均为Κ链。Western blot试验结果显示,6株单克隆抗体均能特异性地识别天然PEDV中的S蛋白。     

猪繁殖与呼吸系统综合征病毒(PRRSV) CH-IR株单克隆抗体的制备

用纯化的猪繁殖与呼吸系统综合征病毒(PRRSV)免疫Balb/c小鼠,应用淋巴细胞杂交瘤技术,使脾细胞与SP2/0骨髓瘤细胞融合,经间接ELISA 筛选,4次有限稀释法克隆,得到1株能稳定分泌抗猪繁殖与呼吸障碍综合征病毒单克隆抗体的杂交瘤细胞株(3D₆),经鉴定,该单抗为IgG2a亚类,杂交瘤细胞的平均染色体数目为99条,杂交瘤细胞培养上清及小鼠腹水单克隆抗体的ELISA效价分别为1∶512和1∶20480。这株单克隆抗体与伪狂犬病毒、猪丹毒、猪细小病毒均不发生交叉反应,显示出良好的特异性。连续培养20代后能稳定分泌抗体,此单克隆抗体的获得为PRRSV的研究及快速诊断方法的建立奠定了基础。     

抗猪戊型肝炎病毒重组蛋白单克隆抗体的制备和鉴定

利用纯化的猪戊型肝炎病毒(HEV)ORF2-M1重组蛋白免疫Balb/c小鼠,采用杂交瘤细胞技术,获得了2株稳定分泌抗HEV ORF2-M1重组蛋白单克隆抗体的杂交瘤细胞株,分别命名为BC4和2A10。经ELISA测定,2株杂交瘤细胞培养上清效价分别为1∶1.60×103和1∶0.80×103,接种小鼠的腹水效价分别为1∶2.56×106和1∶1.28×106。2株单抗均能特异性识别重组ORF2-M1蛋白,但它们识别ORF2-M1蛋白的不同表位。间接免疫荧光试验证实,2株单抗具有良好的特异性,均能够识别HEV。     

一种犬细小病毒基因工程抗体的制备

本研究旨在利用HEK-293细胞系制备鼠源犬细小病毒（canine parovirus，CPV）基因工程抗体并检测其生物活性。通过抗体亚型检测试剂盒检测CPV单克隆抗体亚型；采用间接ELISA检测CPV单克隆抗体的亲和力和特异性；经RACE-PCR获得CPV单克隆抗体的可变区序列，将可变区序列与鼠源抗体恒定区序列连接；分别构建真核表达载体pcDNA3.1（+）-L和pcDNA3.1（+）-H，将载体共转染HEK-293细胞，采用血凝抑制与中和试验的方法检测鼠源CPV基因工程抗体生物活性；采用HEK-293F细胞悬浮表达并用间接ELISA方法检测鼠源CPV基因工程抗体的表达量；用Protein A亲和层析柱纯化鼠源CPV基因工程抗体后进行SDS-PAGE鉴定；间接免疫荧光检测纯化后鼠源CPV基因工程抗体的活性。结果显示，CPV单克隆抗体亚型为IgG_2b，亲和力常数6个Ka平均值为1.02×10¹¹ L/mol，只与CPV VLPs发生反应。琼脂糖凝胶电泳结果显示，试验成功构建真核表达载体pcDNA3.1（+）-L和pcDNA3.1（+）-H；HEK-293和HEK-293F细胞培养上清液血抑效价分别为1∶2⁴和1∶2⁶，中和试验结果显示，HEK-293和HEK-293F细胞培养上清液中和效价分别为1∶152和1∶1 290；鼠源CPV基因工程抗体在HEK-293F细胞中的表达量为5.97 mg/L，SDS-PAGE分析在55和25 ku处出现条带，表明鼠源CPV基因工程抗体成功在HEK-293F细胞中表达并纯化。间接免疫荧光检测结果表明，纯化后鼠源CPV基因工程抗体具有良好的生物活性。本研究在HEK-293F细胞中成功表达具有中和活性、纯度较高的鼠源CPV基因工程抗体，为今后CPV基因工程抗体药物的研发奠定基础。     

Clinical use of serum parvovirus and distemper virus antibody titers for determining revaccination strategies in healthy dogs

OBJECTIVE: To assess whether serum canine parvovirus (CPV) and canine distemper virus (CDV) antibody titers can be used to determine revaccination protocols in healthy dogs. DESIGN: Case series. ANIMALS: 1,441 dogs between 6 weeks and 17 years old. PROCEDURE: CPV and CDV antibody titers in serum samples submitted to a commercial diagnostic laboratory were measured by use of indirect fluorescent antibody (IFA) tests. On the basis of parallel measurements of CPV and CDV serum antibody titers in 61 paired serum samples determined by use of hemagglutination inhibition and serum neutralization methods, respectively, we considered titers > or = 1:5 (IFA test) indicative of an adequate antibody response. RESULTS: Age, breed, and sex were not significantly associated with adequate CPV- or CDV-specific antibody responses. Of 1,441 dogs, 1,370 (95.1%) had adequate and 71 (4.9%) had inadequate antibody responses to CPV, whereas 1,346 of 1,379 (97.6%) dogs had adequate and 33 (2.4%) had inadequate responses to CDV. Vaccination histories were available for 468 dogs (468 for CPV, 457 for CDV). Interval between last vaccination and antibody measurement was 1 to 2 years for the majority (281/468; 60.0%) of dogs and 2 to 7 years for 142 of 468 (30.3%) dogs. Interval was < 1 year in only 45 of 468 (9.6%) dogs. CONCLUSIONS AND CLINICAL RELEVANCE: The high prevalence of adequate antibody responses (CPV, 95.1%; CDV, 97.6%) in this large population of dogs suggests that annual revaccination against CPV and CDV may not be necessary.     

Association between cancer chemotherapy and canine distemper virus, canine parvovirus, and rabies virus antibody titers in tumor-bearing dogs.

OBJECTIVE: To determine the association between cancer chemotherapy and serum canine distemper virus (CDV), canine parvovirus (CPV), and rabies virus antibody titers in tumor-bearing dogs. DESIGN: Prospective study. ANIMALS: 21 client-owned dogs with various malignancies and 16 client-owned dogs with lymphoma. PROCEDURE: In study A, serum antibody titers were measured by use of hemagglutination inhibition (CPV titers) or serum neutralization (CDV titers) before and at least 1 month after initiation of chemotherapy. Baseline values were compared with values obtained from a control population of 122 healthy dogs seen for routine revaccination. Titers were considered protective at > or = 1:96 for CDV and > or = 1:80 for CPV. In study B, serum IgG titers were measured by use of immunofluorescent assay (CDV and CPV titers) and rapid fluorescent focus inhibition test (RFFIT, rabies titers) at baseline and again at weeks 5, 8, and 24 of a standard chemotherapy protocol for treatment of lymphoma. An IgG titer of > or = 1:50 was considered protective for CPV and CDV. An RFFIT titer of > or = 0.5 U/ml was considered protective for rabies virus. RESULTS: Significant changes were not detected in CDV, CPV, and rabies virus titers following chemotherapy in tumor-bearing dogs. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that established immunity to CDV, CPV, and rabies virus from previous vaccination is not significantly compromised by standard chemotherapy used to treat tumor-bearing dogs.     

犬细小病毒核酸疫苗、重组活载体疫苗与弱毒疫苗免疫犬实验研究

分别用犬细小病毒（CPV）核酸疫苗（pVCPV-VP2）、CPV重组活载体疫苗（CAV2／CPV）与CPV弱毒疫苗对犬进行了免疫试验,以检测不同CPV疫苗的免疫原性。采用CPVELISA、CPVHI与CPV微量中和试验检测免疫犬的体液免疫水平,采用淋巴细胞转化试验检测犬的细胞免疫水平。结果,pVCPV—VP2和CAV2／CPV均能诱导机体产生抗CPVELISA抗体与抗CPV中和抗体,但是pVCPV-VP2不能诱导机体产生可检测的抗CPVHI抗体,而CAV2／CPV能够诱导机体产生抗CPVHI抗体。淋巴细胞转化试验结果,pVCPV-VP2和CAV2／CPV免疫犬的外周血淋巴细胞对ConA与CPV的刺激均出现明显的增殖反应。结果表明,pVCPV—VP2和CAV2／CPV免疫犬均能诱导机体产生抗CPV的特异性体液免疫反应和细胞免疫反应,两者所表达的VP2蛋白均具有较好的免疫原性。CAV2／CPV以及pVCPV—VP2和CAV2／CPV联合免疫犬的抗CPV体液免疫水平和细胞免疫水平均比用pVCPV—VP2单独免疫犬的体液免疫水平和细胞免疫水平高。但CAV2／CPV诱导机体产生的抗CPV特异性免疫反应仍然比CPV弱毒疫苗诱导机体产生的抗CPV特异性免疫反应弱。另外,CAV2／CPV还能诱导机体产生抗CAV-2的特异性免疫反应。     

Serologic evaluation of vaccinated American river otters

The Oklahoma Department of Wildlife Conservation acquired 20 American river otters (Lutra canadensis) between 1984 and 1985 for reintroduction into Oklahoma waterways. In 1985, 10 otters were evaluated for serum antibody titers after vaccination with canine distemper virus, canine adenovirus type 2, canine parvovirus (CPV), feline panleukopenia virus (FPV), feline rhinotracheitis virus (FRV), and feline calicivirus. Prevaccination serum-virus neutralization (SVN) antibody to feline rhinotracheitis virus was found in 2 otters and to feline calicivirus in 1 otter. Using an indirect fluorescent antibody (IFA) assay, prevaccination antibody to CPV and FPV was found in 2 otters. A significant increase in SVN antibody titers was found after vaccination of otters with canine adenovirus type 2 (6 of 8 animals) and feline calicivirus (1 of 8 animals). One of 8 otters developed significant antibody titers to CPV and FPV, as measured by IFA assay. Otters did not develop SVN antibody titers to canine distemper virus after vaccination. Antigens of feline leukemia virus, using ELISA, or antibodies to feline infectious peritonitis, using IFA assay, were not found in the 20 otters.     

Neutralizing antibodies against feline parvoviruses in nondomestic felids inoculated with commercial inactivated polyvalent vaccines

The virus neutralization (VN) antibody titers of serum samples from 18 individuals representing 8 carnivore species vaccinated with commercial polyvalent vaccines optimized for domestic cats containing inactivated feline panleukopenia virus (FPLV) were evaluated against canine parvovirus type 2 (CPV2). In addition, the titers among 5 individuals from 4 carnivore were evaluated against antigenic variants of feline parvoviruses; FPLV, CPV2, CPV2a, CPV2b, CPV2c, mink enteritis virus type 1 (MEV1) and MEV2. The polyvalent vaccines induced cross-reactive VN titers against antigenic variants of feline parvoviruses in nondomestic felids. However, we observed very low cross-reactive VN antibody in lions and Siberian tigers, therefore we should pay attention to CPV infections in these animals even if they were vaccinated with inactivated FPLV vaccines.     

抗犬细小病毒纳米抗体的制备及其中和活性鉴定

【目的】 建立抗犬细小病毒（CPV）纳米抗体（Nb）库,从中筛选出具有中和活性的Nb。【方法】 以高免比格犬脾脏组织cDNA进行重链可变区（VH）扩增,与pBSD载体连接,构建pBSD-Nb库。结合细菌展示、流式细胞仪检测,在pBSD-Nb库中筛选高亲和力的Nb,获得阳性克隆并测序。利用Primer Premier 5.0软件设计Nb基因的上、下游引物,将阳性克隆质粒中Nb基因片段进行PCR扩增。利用pET-27b表达目的蛋白,通过变性、复性手段纯化目的蛋白,用SDS-PAGE分析纯化后的蛋白。将Nb包被96孔板,采用ELISA法检测Nb对CPV的亲和力。通过病毒微量中和试验检测Nb抑制CPV感染猫肾细胞（F81）的情况。【结果】 PCR扩增结果显示,在384 bp处可见明显条带,与预期大小相符,证明pBSD-Nb库构建成功。细菌展示后,流式细胞术检测结果显示,有9株阳性峰偏移率高的Nb,分别命名为Nb1、Nb2、Nb3、Nb4、Nb5、Nb6、Nb7、Nb8和Nb9。PCR扩增9株Nb基因片段,获得384 bp的条带。SDS-PAGE结果显示,在约14 ku处有一条带,说明成功获得纯化蛋白。ELISA检测结果表明,9株Nb中有6株Nb对CPV的亲和力较强。体外病毒中和试验检测发现,1株Nb能够中和病毒,抑制F81细胞病变,中和病毒的有效浓度为0.05 mg/mL。【结论】 本研究成功建立pBSD-Nb库,筛选出6株对CPV具有高亲和力的Nb,并成功获得1株具有中和活性的Nb,为CPV治疗性抗体制剂的开发提供了新的思路。     

Response of pups with maternal derived antibody to modified-live canine parvovirus vaccine

The AA reports the results of vaccination against canine parvovirus (CPV) of pups with maternal antibody, utilizing a modified-live virus (MLV) CPV vaccine having a titer of 10⁷ TCID₅₀/dose. This vaccine was shown to be effective also when HI antibody titers of pups were ≤ 1:80.     

Prevalence of positive antibody test results for canine parvovirus (CPV) and canine distemper virus (CDV) and response to modified live vaccination against CPV and CDV in dogs entering animal shelters

Canine parvovirus (CPV) and canine distemper virus (CDV) infections are relatively common in animal shelters and are important population management issues since the immune status of incoming dogs is usually unknown. This study aimed to determine the prevalence of positive antibody test results for CPV and CDV in incoming dogs aged ≥ 4 months and to measure antibody response over 2 weeks following vaccination with a modified live vaccine (MLV). Dogs aged 4-24 months entering an adoption-guarantee shelter (Shelter 1, n=51) and aged ≥ 4 months entering a limited admission shelter (Shelter 2; n=51) were enrolled. Dogs from Shelter 1 had been vaccinated with MLV at a municipal shelter 5 days before enrollment, whereas dogs from Shelter 2 had no known history of vaccination at enrollment. Sera were obtained on day 1, immediately prior to CPV/CDV MLV, and tested using an in-clinic ELISA kit to detect CPV/CDV antibodies. Dogs negative for CPV and/or CDV were retested at day 6-8 and those dogs still negative at day 6-8 were retested at day 13-15. Prior to CPV/CDV MLV on day 1, more dogs tested positive for CPV (Shelter 1 - 68.6%; Shelter 2 - 84.3%) than for CDV (Shelter 1 - 37.3%; Shelter 2 - 41.2%). On day 1, prior to MLV, all spayed/neutered animals tested CPV antibody-positive (n=17/102) and CPV antibody-positive dogs were older than serologically negative dogs (Shelter 1, P=0.0029; Shelter 2, P=0.0042). By day 13-15, almost all dogs were CPV antibody-positive (Shelter 1 - 97.9%; Shelter 2 - 100.0%) and CDV antibody-positive (Shelter 1 - 93.8%; Shelter 2 - 97.8%). MLV induces protective antibody titers against CPV/CDV in almost all dogs after 13-15 days.     

中药穿心莲对新城疫HI抗体滴度的影响

1日龄肉仔鸡随机分为A、B、C、D、E、F、G7个试验组,每组组内设2个重复小组,每个重复小组35只鸡。A、B、C、D、E、F试验组添加穿心莲,G组不添加。各组均对新城疫进行首免和二免。结果发现,穿心莲能显著提高肉鸡的新城疫HI抗体滴度水平。另外,穿心莲的抗体滴度水平有一定的剂量依赖性,随着剂量的上升效果有提高的趋势。